Literature DB >> 17372907

Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration.

Carmen Eckerich1, Svenja Zapf, Regina Fillbrandt, Sonja Loges, Manfred Westphal, Katrin Lamszus.   

Abstract

The c-Met receptor and its ligand scatter factor/hepatocyte growth factor (SF/HGF) are strongly overexpressed in malignant gliomas. Signaling through c-Met as well as exposure to hypoxia can stimulate glioma cell migration and invasion. In several cancer cell types, hypoxia was shown to activate the c-met promoter, which contains hypoxia inducible factor-1 (HIF-1) binding sites. We hypothesized that hypoxia might upregulate c-Met also in glioma cells. Analyzing 18 different glioblastoma cell lines and 10 glioblastoma primary cultures, we found that in 50% of both the cell lines and the primary cultures c-Met protein levels were increased following exposure to hypoxia. Upregulation of c-met in response to hypoxia was also detected at the transcriptional level. In all primary cultures and in 16 of the 18 cell lines (89%), HIF-1 alpha levels were increased by hypoxia. Transfection of siRNA against HIF-1 alpha abgrogated the hypoxic induction of c-Met, suggesting that c-Met expression is upregulated by a HIF-1 alpha-dependent mechanism. Hypoxia sensitized glioblastoma cell lines which showed hypoxic induction of c-Met to the motogenic effects of SF/HGF. These findings suggest that approximately half of all human glioblastomas respond to hypoxia with an induction of c-Met, which can enhance the stimulating effect of SF/HGF on tumor cell migration. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17372907     DOI: 10.1002/ijc.22679

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  61 in total

1.  Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures.

Authors:  David Zagzag; Mine Esencay; Olga Mendez; Herman Yee; Iva Smirnova; Yuanyuan Huang; Luis Chiriboga; Eugene Lukyanov; Mengling Liu; Elizabeth W Newcomb
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

2.  The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival.

Authors:  Qing-le Liang; Zheng-ying Mo; Ping Wang; Xiao Li; Zhi-xiang Liu; Zhang-ming Zhou
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

Review 3.  Biology of angiogenesis and invasion in glioma.

Authors:  Matthew C Tate; Manish K Aghi
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

4.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

5.  Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

Authors:  Vesselina G Cooke; Valerie S LeBleu; Doruk Keskin; Zainab Khan; Joyce T O'Connell; Yingqi Teng; Michael B Duncan; Liang Xie; Genta Maeda; Sylvia Vong; Hikaru Sugimoto; Rafael M Rocha; Aline Damascena; Ricardo R Brentani; Raghu Kalluri
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

6.  Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres.

Authors:  Olga Méndez; Jiri Zavadil; Mine Esencay; Yevgeniy Lukyanov; Daniel Santovasi; Shu-Chi Wang; Elizabeth W Newcomb; David Zagzag
Journal:  Mol Cancer       Date:  2010-06-01       Impact factor: 27.401

7.  Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management.

Authors:  Laura M S Seeber; Ronald P Zweemer; René H M Verheijen; Paul J van Diest
Journal:  Obstet Gynecol Int       Date:  2010-02-14

8.  HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression.

Authors:  Jacqueline Kessler; Antje Hahnel; Henri Wichmann; Swetlana Rot; Matthias Kappler; Matthias Bache; Dirk Vordermark
Journal:  BMC Cancer       Date:  2010-11-04       Impact factor: 4.430

9.  Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Authors:  Yong Qin; Jason Roszik; Chandrani Chattopadhyay; Yuuri Hashimoto; Chengwen Liu; Zachary A Cooper; Jennifer A Wargo; Patrick Hwu; Suhendan Ekmekcioglu; Elizabeth A Grimm
Journal:  Mol Cancer Ther       Date:  2016-07-25       Impact factor: 6.261

10.  c-Met signaling promotes IL-6-induced myeloma cell proliferation.

Authors:  Håkon Hov; Erming Tian; Toril Holien; Randi Utne Holt; Thea K Våtsveen; Unn-Merete Fagerli; Anders Waage; Magne Børset; Anders Sundan
Journal:  Eur J Haematol       Date:  2009-01-06       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.